1 withdrawn. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Withdrawn 1 |
Follow Stage IVA Extrahepatic Bile Duct Cancer: new trials by email Literature Review of Stage IVA Extrahepatic Bile Duct Cancer trials Research Report on Stage IVA Extrahepatic Bile Duct Cancer
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma Cisplatin, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis - Non-Resectable Cholangiocarcinoma, Recurrent Cholangiocarcinoma | Phase 1 | Withdrawn | Mayo Clinic | 2017-05-01 | 2017-05-30 |
Bile Duct Neoplasms (1) · Cholangiocarcinoma (1) · Klatskin Tumor (1)
Adenocarcinoma (1) · Bile Duct Diseases (1) · Biliary Tract Diseases (1) · Biliary Tract Neoplasms (1) · Carcinoma (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Glandular and Epithelial (1)
1,2-diaminocyclohexaneplatinum II citrate (1) · Cisplatin (1) · Gemcitabine (1) · Platinum (1) · ricolinostat (1)
Mayo Clinic (1)
United States (1)
Kabir Mody (1)
P30CA015083 (1)